Pathogenetic mechanisms underlying myelodysplastic syndromes

Myelodysplastic Syndromes: Clinical and Biological Advances

Volumn , Issue , 2005, Pages 63-94

  Peter, L Greenberg ^a  

^a STANFORD CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84928639100     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511545269.004     Document Type: Chapter

References (159)

1. Greenberg, P. L. (2000). The myelodysplastic syndromes. In Hematology: Basic Principles and Practice, 3rd edn, ed. R. Hoffman, E. Benz, S. Shattil, and H. Cohen. New York: Churchill Livingstone, pp. 1106–29.
2. Metcalf, D. (1986). The molecular biology and functions of the granulocytemacrophage colony stimulating factors. Blood, 67, 257–67.
3. Verbeek, W., Vehmeyer, K., Wormann, B. et al. (1995). The effect of stem-cell factor, interleukin-3 and erythropoietin on in vitro erythropoiesis in myelodysplastic syndromes. J. Cancer Res. Clin. Oncol., 121, 338–42.
4. Williams, G. T., Smith, C., Spooncer, E., Dexter, T. M., and Taylor, D. R. (1990). Haemopoietic colony stimulating factorspromote cell survivalby suppressing apoptosis. Nature, 343, 76.
5. Jacobs, A., Janowska, A., Caro, J. et al. (1989). Circulating erythropoietin in patients with myelodysplastic syndrome. Br. J. Haematol., 73, 36.
6. Greenberg, P. L., MacKichan, M., Negrin, R., Renick, M., and Ginzton, N. (1990). Production of granulocyte colony stimulating factor by normal andmyelodysplastic syndrome peripheral blood cells. Blood, 76(suppl. 1), 146.
7. Verhoef, G. E., DeSchouwer, P., Ceuppens, J. L. et al. (1992).Measurement of serum cytokine levels in patients with myelodysplastic syndromes. Leukemia, 6, 1268.
8. Axelrad, A. (1990). Some hemopoietic negative regulators. Exp. Hematol., 18, 143–50.
9. Deeg, H. J., Beckham, C., Loken, M. R. et al. (2000). Negative regulators of hemopoiesis and stroma function in patientswithmyelodysplastic syndrome. Leuk. Lymphoma, 37, 405–14.
10. Gersuk, G. M., Lee, J., Beckham, C. A., Anderson, J., and Deeg, J. H. (1996). Fas (CD95) receptor and Fas-ligand expression in bone marrowcells frompatientswith myelodysplastic syndrome. Blood, 88, 1122.
11. Pruneri, G., Bertolini, F., Soligo, D. et al. (1999). Angiogenesis in myelodysplastic syndromes. Br. J. Cancer, 81, 1398–401.
12. Greenberg, P. L. (1992).Treatment ofMDSwith hemopoietic growth factors. Semin. Oncol., 19, 106.
13. Nagler, A., Ginzton, N., Bangs, C. et al. (1990). In vitro differentiative and proliferative effects of human recombinant colony-stimulating factors on marrow hemopoiesis in myelodysplastic syndromes. Leukemia, 4, 193–202.
14. Broxmeyer, H. E., Lu, L., Platzer, E. et al. (1983). Comparative analysis of the influence of human gamma, alpha, and beta interferons on human multipotential, erythroid and granulocyte-macrophage progenitor cells. J. Immunol., 131, 1300–5.
15. Peetre, C., Gullberg, U., Nilsson, E. et al. (1986). Effects of recombinant tumor necrosis factor on proliferation and differentiation of leukemic and normal hemopoietic cells in vitro: relationship to cell surface receptor. J. Clin. Invest., 78, 1694–700.
16. Murase, T., Hofta, T., Saito, H. et al. (1987). Effect of recombinant human tumor necrosis factoronthe colony growth ofhumanleukemia progenitor cellsandnormal hematopoietic progenitor cells. Blood, 69, 467–72.
17. Shetty, V., Mundle, S., Alvi, S. et al. (1996).Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes. Leuk. Res., 20, 891–900.
18. Budel, L. M., Dong, F., Lowenberg, B. et al. (1995). Hematopoietic growth factor receptors: structure variations and alternatives of receptor complex formation in normal hematopoiesis and in hematopoietic disorders. Leukemia, 9, 553–61.
19. Bouscary, D., De Vos, J., Guesnu, M. et al. (1997). Fas/Apo-1 (CD95) expression and apoptosis in patients with yelodysplastic syndromes. Leukemia, 11, 839–45.
20. Zang, D. Y., Goodwin, R., Loken, M. R., Bryant, E., and Deeg, H. J. (2001). Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis. Blood, 98, 3058–65.
21. Goossens, V., Grooten, J., De Vos, K., and Fiers, W. (1995). Direct evidence for tumor necrosis factor-induced itochondrial reactive oxygen intermediates and their involvement in cytotoxicity. Proc. Natl Acad. Sci. U.S.A., 92, 8115.
22. Peddie, C., Wolf, R., McLellan, L., Collins, A. R., and Bowen, T. (1997). Oxidative DNA damage in CD34+ myelodysplastic cells is associated with intracellular redox changes and elevated plasma tumour necrosis factor-α concentration. Br. J. Haematol., 99, 625.
23. Farquhar, M. J. and Bowen, D. (2003). Oxidative stress and the myelodysplastic syndromes. Int. J. Hematol., 77, 342–50.
24. Maciejewski, J. P., Selleri, C., Anderson, S., and Young, N. (1995). Fas antigen expression in CD34+ human marrow cells is induced by interferon-α and tumor necrosis factor-α and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood, 85, 3183.
25. Gersuk, G., Beckham, C., Loken, M. et al. (1998). A role for TNF-α, Fas and Fas ligand inmarrowfailure ssociatedwithmyelodysplastic syndrome.Br. J.Haematol., 103, 176–88.
26. Massague, J. (1987). The TGF-beta family of growth and differentiation factors. Cell, 49, 437–8.
27. Sing, G. K., Keller, J., Ellingsworth, J. R. et al. (1988). Transforming growth factor beta selectively inhibits normal and leukemic human bone marrow cell growth in vitro. Blood, 72, 1504–11.
28. Broxmeyer, H. E., Sherry, B., Cooper, S., Lu, L. et al. (1993). Comparative analysis of the human macrophage inflammatory protein family of cytokines (chemokines) on proliferation of human myeloid progenitor cells. J. Immunol., 150, 3448–58.
29. Schmidt-Mende, J., Tehranchi, R., Forsblom, A. M., Joseph, B. et al. (2001).Granulocyte colony-stimulating factor inhibits Fas-triggered apoptosis in bone marrowcells isolated from patients with refractory anemia with ringed sideroblasts. Leukemia, 15, 742–51.
30. Tehranchi, R., Fadeel, B., Forsblom, A. M. et al. (2003). Granulocyte colonystimulating factor inhibits spontaneous cytochrome c release and mitochondriadependent apoptosis of myelodysplastic syndrome hematopoietic progenitors. Blood, 101, 1080–6.
31. Aizawa, S., Nakano, M., Iwase, O. et al. (1999). Bone marrow stroma from refractory anemia of myelodysplastic syndrome is defective in its ability to support normal CD34-positive cell proliferation and differentiation in vitro. Leuk. Res., 23, 239–46.
32. Tennant, G. B., Walsh, V., Truran, L. N. et al. (2000). Abnormalities of adherent layers grown from bone marrow of patients with myelodysplasia. Br. J. Haematol., 111, 853–62.
33. Coutinho, L. H., Geary, C., Chang, J., Harrison, C., and Testa, N. G. (1990). Functional studies of bonemarrowhaemopoietic and stromal cells inthemyelodysplastic syndrome (MDS). Br. J. Haematol., 75, 16–25.
34. Tauro, S., Hepburn, M., Peddie, C. M., Bowen, D. T., and Pippard, M. J. (2002). Functional disturbance of marrowstromal microenvironment in themyelodysplastic syndromes. Leukemia, 16, 785–90.
35. Borojevic, R., Roela, R., Rodarte, R. S. et al. (2004). Bone marrow stroma in childhood myelodysplastic syndrome: composition, ability to sustain hematopoiesis in vitro, and altered gene expression. Leuk. Res., 28, 831–44.
36. Duhrsen, U., Martinez, T., Vohwinkel, G. et al. (2001). Effects of vascular endothelial and platelet-derived growth factor receptor inhibitors on long-term cultures from normal human bone marrow. Growth Factors, 19, 1–17.
37. Carvalho, M. A., Arcanjo, K., Silva, L. C., and Borojevic, R. (2000). The capacity of connective tissue stromas to sustain myelopoiesis depends both upon the growth factors and the local intercellular environment. Biol. Cell, 92, 605–14.
38. Ferrara, N. and Alitalo, K. (1999). Clinical applications of angiogeneic growth factors and their inhibitors. Nat. Med., 5, 1359–64.
39. Bellamy, W. T., Richer, L., Sirjani, D. et al. (2001). Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immaturemyeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood, 97, 1427–34.
40. List, A. F. (2001).Vascular endothelial growth factor signaling pathway as an emerging target in hematologic malignancies. Oncologist, 6(suppl. 5), 24–31.
41. Zhang, L., Eastmond, D., and Smith, M. T. (2002). The nature of chromosomal aberrations detected in humans exposed to benzene. Crit. Rev. Toxicol., 32, 1–42.
42. Aguayo, A., Kantarjian, H., Manshouri, T. et al. (2000). Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood, 96, 2240–5.
43. Platanias, L. C. (2003).Map kinase signaling pathways and hematologic malignancies. Blood, 101, 4667–79.
44. Verma, A., Deb, D., Sassano, A. et al. (2002).Activation of the p38 mitogen-activated protein kinase mediates the suppressive effects of type I interferons and transforming growth factor-beta on normal hematopoiesis. J. Biol. Chem., 277, 7726–35.
45. Verma, A., Deb, D., Sassano, A. et al. (2002). Cutting edge: activation of the p38 mitogen-activated protein kinase signaling pathway mediates cytokine-induced hemopoietic suppression in aplastic anemia. J. Immunol., 168, 5984–8.
46. Cortelezzi, A., Cattaneo, C., Cristiani, S. et al. (2000). Non-transferrin-bound iron in myelodysplastic syndromes: a marker of ineffective erythropoiesis? Hematol. J., 1, 153–8.
47. Hofmann, W. K., De Vos, S., Komor, M. et al. (2002). Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow. Blood, 100, 3553–60.
48. Bowen, D., Wang, L., Frew, M., Groves, R., and Groves, M.(2003).Antioxidant enzyme expression in myelodysplastic and acute myeloid leukemia bone marrow: further evidence of a pathogenetic role for oxidative stress? Haematologica, 88, 1070–2.
49. Hershko, C., Link, G., and Cabantchik, I. (1996). Pathophysiology of iron overload. Ann. N.Y. Acad. Sci., 850, 191.
50. Olivieri, N. and Brittenham, G. (1997). Iron-chelating therapy and the treatment of thalassemia. Blood, 89, 739.
51. Jensen, P.D., Heickendorff, L., Pedersen, B. et al. (1996). The effect of iron chelation on haemopoiesis inMDSpatientswith transfusional iron overload. Br. J.Haematol., 94, 288–99.
52. Pootrakul, P., Sinrankapracha, P., Sankote, J., Kachintorn, U. et al. (2003). Clinical trial of deferiprone iron chelation therapy in beta-thalassaemia/haemoglobin E patients in Thailand. Br. J. Haematol., 122, 305–10.
53. Hamblin, T. (1992). Immunologic abnormalities in myelodysplastic syndromes. Hematol. Oncol. Clin. North Am., 6, 571.
54. Bynoe, A. G., Scott, C., Ford, P. et al. (1983). DecreasedThelper cells in themyelodysplastic syndromes. Br. J. Haematol.54, 97.
55. Knox, S. J., Greenberg, P., Anderson, R.W. et al. (1983). Studies of T lymphocytes in preleukemic disorders and acute nonlymphocytic leukemia: in vitro radiosensitivity, mitogenic responsiveness, colony formation, and enumeration of lymphocytic subpopulations. Blood, 61, 449.
56. Richert-Boe, K. E. and Bagby, G. J. (1992). In vitro hematopoiesis inmyelodysplasia: liquid and soft-gel culture studies. Hematol. Oncol. Clin. North Am., 6, 543–56.
57. Janssen, J.W. G., Buschle, M., Layton, M. et al. (1989). Clonal analysis ofmyelodysplastic syndromes: evidence of multipotent stem cell origin. Blood, 73, 248.
58. Abrahamson, G., Boultwood, J., Madden, J. et al. (1991). Clonality of cell populations in refractory anaemia using combined approach of gene loss and X linked restriction fragment length polymorphism methylation analysis. Br. J. Haematol., 79, 550.
59. Anastasi, J., Feng, J., Le Beau, M. M. et al. (1993).Cytogenetic clonality inmyelodysplastic syndromes studied with fluorescence in situ hybridization: lineage, response to growth factor therapy and clonal expansion. Blood, 81, 1580.
60. Tsukamot, N., Morita, K., Maehara, T. et al. (1993). Clonality in MDS: demonstration of pluripotent stem cell origin using X linked restriction fragment length polymorphisms. Br. J. Haematol., 83, 589.
61. van Kamp, H., Fibbe, W., Jansen, R. P. M. et al. (1992). Clonal involvement of granulocytes and monocytes, but not of T and B lymphocytes and natural killer cells in patients with myelodysplasia: analysis by X linked restriction fragment length polymorphisms and polymerase chain reaction of the phosphoglycerate kinase gene. Blood, 80, 1774.
62. Culligan, D. J., Cachai, P., Whittaker, J. et al. (1992). Clonal lymphocytes are detectable in only some cases of MDS. Br. J. Haematol., 81, 346.
63. Kroef, M. J. P. L., Fibbe, W., Mout, R. et al. (1993).Myeloid but not lymphoid cells carry the 5q deletion: polymerase chain reaction analysis of loss of heterozygosity using mini repeat sequences on highly purified cell fractions. Blood, 81, 1849.
64. Greenberg, P. L. (1996). Biologic and clinical implications of marrowculture studies in the myelodysplastic syndromes. Semin. Hematol., 33, 163–75.
65. Merchav, S., Nielson, O., Rosenbaum, H. et al.(1990). In vitro studies of erythropoietin-dependent regulation of erythropoiesis in myelodysplastic syndromes. Leukemia, 4, 771–4.
66. Clark, D. M. and Lambert, I. (1990).Apoptosis is a commonhistopathological finding inmyelodysplasia: the correlate of ineffective haematopoiesis. Leuk. Lymphoma, 2, 415.
67. Raza, A., Gezer, S., Mundle, S. et al. (1995). Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood, 86, 268.
68. Raza, A., Mundle, S., Iftikhar, A. et al. (1995). Simultaneous assessment of cell kinetics and programmed cell death in bone marrow biopsies of myelodysplastics reveals extensive apoptosis as the probable basis for ineffective hematopoiesis. Am. J. Hematol., 48, 143.
69. Rajapaksa, R., Ginzton, N., Rott, L., and Greenberg, P. L. (1996). Altered oncogene expression and apoptosis in myelodysplastic syndrome marrow cells. Blood, 88, 4275–87.
70. Greenberg, P. L. (1998). Apoptosis and its role in MDS: implications for disease natural history and treatment. Leukemia Res., 22, 1123–36.
71. Shimazaki, K., Ohshima, K., Suzumiya, J., Kawasaki, C., and Kikuchi, M. (2000). Evaluation of apoptosis as a prognostic factor in myelodysplastic syndromes. Br. J. Haematol., 110, 584–90.
72. Huh, Y. O., Jilani, I., Estey, E. et al. (2002). More cell death in refractory anemia with excess blasts in transformation than in acutemyeloid leukemia. Leukemia, 16, 2249–52.
73. Ali, A., Mundle, S., Ragasa, D. et al. (1999). Sequential activation of caspase- 1 and caspase-3-like proteases during apoptosis in myelodysplastic syndromes. J. Hematother. Stem Cell Res., 8, 343–56.
74. Hellstrom-Lindberg, E., Schmidt-Mende, J., Forsblom, A. M. et al. (2001). Apoptosis in refractory anaemia with ringed sideroblasts is initiated at the stem cell level and associated with increased activation of caspases. Br. J. Haematol., 112, 714–26.
75. Parker, J., Mufti, G., Rasool, F. et al. (2000). The role of apoptosis, proliferation and the Bcl2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood, 96, 3932–8.
76. Korsmeyer, S. (1995). Regulators of cell death. Trends Genet., 11, 101.
77. Reed, J. C. (1997). Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies. Semin. Hematol., 34, 9.
78. Davis, R. E. and Greenberg, P. (1998). Bcl-2 expression by myeloid precursors in myelodysplastic syndromes: impact on disease progression. Leuk. Res., 22, 767–77.
79. Boudard, D., Vasselon, C., Bertheas, M. F. et al. (2002). Expression and prognostic significance of Bcl-2 family proteins inmyelodysplastic syndromes.Am. J.Hematol., 70, 115–25.
80. Jacobs, R. A., Cornbleet, M., Vardiman, J. et al. (1986). Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes. Blood, 67, 1765.
81. Pedersen-Bjergaard, J., Philip, P., Larsen, S. O. et al. (1990). Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia. Blood, 76, 1083.
82. Horiike, S., Taniwaki, M., Misawa, S. et al. (1988). Chromosome abnormalities and karyotypic evolution in 83 patients with myelodysplastic syndrome and predictive value for prognosis. Cancer, 62, 1129.
83. Rossi, G., Pelizzari, A., Bellotti, D., Tonelli, M., and Barlati, S. (2000). Cytogenetic analogy between myelodysplastic syndrome and acute myeloid leukemia of elderly patients. Leukemia, 14, 636–41.
84. Carroll, M., Tomasson, M., Barker, G. F., Golub, T. R., and Gilliland, D. G. (1996). The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways. Proc. Natl Acad. Sci. U.S.A., 93, 14845–50.
85. Magnusson, M. K., Meade, K., Nakamura, R., Barrett, J., and Dunbar, C. E. (2002). Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene. Blood, 100, 1088–91.
86. Yunis, J. J., Boot, A. J. M., Mayer, M. G., and Bos, J. L. (1989). Mechanisms of ras mutation in myelodysplastic syndrome. Oncogene, 4, 609.
87. Padua, R. A., Gunn, B., Al-Sabah, A. I. et al. (1998). RAS, FMS Leukemia, 12, 887–92.
88. Shih, L. Y., Huang, C., Wang, P. N. et al. (2004). Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia. Leukemia, 18, 466–75.
89. Paquette, R. L., Landow, E., Pierre, R.V. et al. (1993). N-ras mutations are associated with poor prognosis and increased risk of leukaemia inmyelodysplastic syndrome. Blood, 82, 590–9.
90. Parker, J. andMufti, G. (1996). Ras andmyelodysplasia: lessons fromthe last decade. Semin. Hematol., 33, 206.
91. Neubauer, A., Greenberg, P., Negrin, R. et al. (1994). Mutations in the ras protooncogenes in patients with myelodysplastic syndromes. Leukemia, 8, 638.
92. Zhang, J. and Lodish, H. (2004). Constitutive activation of the MEK/ERK pathway mediates all effects of oncogenic H-ras expression in primary erythroid progenitors. Blood, 104, 1679–87.
93. Greenberg, P., Cox, C., Le Beau, M. M. et al. (1997). International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 89, 2079–88.
94. Ridge, S. A., Worwood, M., Oscier, D. et al. (1990). FMS mutations in myelodysplastic, leukemic, and normal subjects. Proc. Natl Acad. Sci. U.S.A., 87, 1377.
95. Tobal, K., Pagliuca, A., Bhatt, B. et al. (1990).Mutation of the human FMS gene (MCSFreceptor) nmyelodysplastic syndromesandacutemyeloid leukemia. Leukemia, 4, 486.
96. Fidler, C., Watkins, F., Bowen, D. T. et al. (2004). NRAS, FLT3 and TP53 mutations in patientswithmyelodysplastic syndromeand a del(5q).Haematologica, 89, 865–6.
97. Hollstein, M., Sidransky, D., Vogelstein, B., andHarris, C. C. (1991). p53 mutations in human cancers. Science, 253, 49.
98. Jonveaux, P., Fenaux, P., Quiquandon, I. et al.(1991).Mutations in the p53 gene in myelodysplastic syndromes. Oncogene, 6, 2243.
99. Wattel, E., Preudhomme, C., Hecquet, B. et al.(1994). P53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood, 84, 3148.
100. Mori, N., Hidai, H., Yokota, J. et al.(1995).Mutations of the p53 gene inmyelodysplastic syndrome and overt leukemia. Leuk. Res., 19, 869.
101. Sugimoto, K., Hirano, N., Toyoshima, H. et al.(1993). Mutations of the p53 gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia. Blood, 81, 3022.
102. Kaneko, H., Misawa, S., Horiike, S. et al. (1995). TP53 mutations emerge at early phase ofmyelodysplastic syndrome and are associated with complex chromosomal abnormalities. Blood, 85, 2189.
103. Kita-Sasai, Y., Horiike, S., Misawa, S. et al. (2001). International prognostic scoring system and TP53mutations are independent prognostic indicators for patientswith myelodysplastic syndrome. Br. J. Haematol., 115, 301–12.
104. Horiike, S., Kita-Sasai, Y., Nakao, M., and Taniwaki, M. (2003).Configuration of the TP53 gene as an independent prognostic parameter of myelodysplastic syndrome. Leuk. Lymphoma, 44, 915–22.
105. Ben-Yehuda, D., Krichevsky, S., Caspi, O. et al. (1996).Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype. Blood, 88, 4296.
106. Horiike, S., Misawa, S., Kaneko, H. et al.(1999). Distinct genetic involvement of the TP53 gene in therapy-related leukemia and myelodysplasia with chromosomal losses of nos 5 and/or 7 and its possible relationship to replication error phenotype. Leukemia, 13, 1235.
107. Side, L. E., Curtiss, N., Teel, K., Kratz, C. et al. (2004). RAS, FLT3, and TP53 mutations in therapy-relatedmyeloid malignancies with abnormalities of chromosomes 5 and 7. Genes Chromosomes Cancer, 39, 217–22.
108. Cilloni, D., Gottardi, E., Messa, F., Fava, M. et al. (2003). Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes. J. Clin. Oncol., 21, 1988–95.
109. Nakao, M., Horiike, S., Fukushima-Nakase, Y., Nishimura, M. et al. (2004). Novel loss-of-function mutations of the haematopoiesis-related transcription factor, acute myeloid leukaemia 1/runt-related transcription factor 1, detected in acute
110. Fidler, C., Watkins, F., Bowen, D. T. et al. (2004). NRAS, FLT3 and TP53 mutations in patientswithmyelodysplastic syndromeand a del(5q).Haematologica, 89, 865–6.
111. Hollstein, M., Sidransky, D., Vogelstein, B., andHarris, C. C. (1991). p53 mutations in human cancers. Science, 253, 49.
112. Jonveaux, P., Fenaux, P., Quiquandon, I. et al.(1991).Mutations in the p53 gene in myelodysplastic syndromes. Oncogene, 6, 2243.
113. attel, E., Preudhomme, C., Hecquet, B. et al.(1994). P53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood, 84, 3148.
114. Mori, N., Hidai, H., Yokota, J. et al.(1995).Mutations of the p53 gene inmyelodysplastic syndrome and overt leukemia. Leuk. Res., 19, 869.
115. Sugimoto, K., Hirano, N., Toyoshima, H. et al.(1993). Mutations of the p53 gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia. Blood, 81, 3022.
116. Kaneko, H., Misawa, S., Horiike, S. et al. (1995). TP53 mutations emerge at early phase ofmyelodysplastic syndrome and are associated with complex chromosomal abnormalities. Blood, 85, 2189.
117. Kita-Sasai, Y., Horiike, S., Misawa, S. et al. (2001). International prognostic scoring system and TP53mutations are independent prognostic indicators for patientswith myelodysplastic syndrome. Br. J. Haematol., 115, 301–12.
118. Horiike, S., Kita-Sasai, Y., Nakao, M., and Taniwaki, M. (2003).Configuration of the TP53 gene as an independent prognostic parameter of myelodysplastic syndrome. Leuk. Lymphoma, 44, 915–22.
119. Ben-Yehuda, D., Krichevsky, S., Caspi, O. et al. (1996).Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype. Blood, 88, 4296.
120. Horiike, S., Misawa, S., Kaneko, H. et al.(1999). Distinct genetic involvement of the TP53 gene in therapy-related leukemia and myelodysplasia with chromosomal losses of nos 5 and/or 7 and its possible relationship to replication error phenotype. Leukemia, 13, 1235.
121. Side, L. E., Curtiss, N., Teel, K., Kratz, C. et al. (2004). RAS, FLT3, and TP53 mutations in therapy-relatedmyeloid malignancies with abnormalities of chromosomes 5 and 7. Genes Chromosomes Cancer, 39, 217–22.
122. Cilloni, D., Gottardi, E., Messa, F., Fava, M. et al. (2003). Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes. J. Clin. Oncol., 21, 1988–95.
123. Nakao, M., Horiike, S., Fukushima-Nakase, Y., Nishimura, M. et al. (2004). Novel loss-of-function mutations of the haematopoiesis-related transcription factor, acute myeloid leukaemia 1/runt-related transcription factor 1, detected in acute myeloblastic leukaemia and myelodysplastic syndrome. Br. J. Haematol., 125, 709–19.
124. Harada, H., Haroda, Y., Niimi, H. et al. (2004).High incidence of somaticmutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia. Blood, 103, 2316–24.
125. Soderholm, J., Kobayashi, H., Mathieu, C., Rowley, J. D., and Nucifora, G. (1997). The leukemia-associated gene MDS1/EVI1 is a new type of GATA-binding transactivator. Leukemia, 11, 352–8.
126. Erpelinck, C., Lowenberg, B., and Delwel, R. (2003). Low expression of MDS1-EVI1-like-1 (MEL1) and EVI1- like-1 (EL1) genes in favorable-risk acute myeloid leukemia. Exp. Hematol., 31, 1066–72.
127. Xu, K., Wang, L., Hao, Y. et al. (1999). Evi-1 and MDS1-Evi-1 genes in pathogenesis of myelodysplastic syndromes and post-MDS acute myeloid leukemia. Chin. Med. J. (Engl.), 112, 1112–18.
128. Shih, L. Y., Lin, T., Wang, P. N. et al. (2004). Internal tandem duplication of fms-like tyrosine kinase 3 is associated with poor outcome in patients with myelodysplastic syndrome. Cancer, 101, 989–98.
129. Horiike, S., Yokota, S., Nakao, M., Iwai, T. et al.(1997). Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation ofmyelodysplasia. Leukemia, 11, 1442–6.
130. Gomes, I., Sharma, T., Edassery, S. et al. (2002). Novel transcription factors in human CD34 antigen-positive hematopoietic cells. Blood, 100, 107–19.
131. Nagamura-Inoue, T., Tamura, T. T., and Ozato, K. (2001). Transcription factors that regulate growth and differentiation of myeloid cells. Int. Rev. Immunol., 20, 83–105.
132. Yordy, J. S. and Muise-Helmericks, R. (2000). Signal transduction and the Ets family of transcription factors. Oncogene, 19, 6503–13.
133. Hsu, T., Trojanowska, M., and Watson, D. K. (2004). Ets proteins in biological control and cancer. J. Cell Biochem., 91, 896–903.
134. Kopp, J. L., Wilder, P., Desler, M. et al. (2004). Unique and selective effects of five Ets family members, Elf3, Ets1, Ets2, PEA3, and PU.1, on the promoter of the type II transforming growth factor-beta receptor gene. J. Biol. Chem., 279, 19407–20.
135. Kim, H. G., De Guzman, C., Swindle, C. S. et al. (2004). The ETS-family transcription factor, PU.1, is necessary for the maintenance of fetal liver hematopoietic stem cells. [Epub ahead of print]. Blood, 104, 3894–900.
136. Kerckaert, J. P., Duterque-Coquillaud, M., Collyn-d’Hooghe, M. et al. (1990). Polymorphism of the proto-oncogene ETS-1 in hematological malignancies. Leukemia, 4, 16–19.
137. Wlodarska, I., Mecucci, C., Marynen, P. et al.(1995). TEL gene is involved in myelodysplastic syndromes with either the typical t(5;12)(q33;p13) translocation or its variant t(10;12)(q24;p13). Blood, 85, 2848–52.
138. Gilliland, D. G. (2002). Molecular genetics of human leukemias: new insights into therapy. Semin. Hematol., 39(suppl. 3), 6–11.
139. Sternberg, D.W. and Gilliland, D. (2004). The role of signal transducer and activator of transcription factors in leukemogenesis. J. Clin. Oncol., 22, 361–71.
140. Hoefsloot, L. H., van Amelsvoort, M., Broeders, L. C. et al. (1997). Erythropoietininduced activation of STAT5 is impaired in the myelodysplastic syndrome. Blood, 89, 1690–700.
141. Ohyashiki, J. H., Iwama, H., Yahata, N. et al. (1999). Telomere stability is frequently impaired in high-risk groups of patients with myelodysplastic syndromes. Clin. Cancer Res., 5, 1155–60.
142. Sashida, G., Ohyashiki, J., Nakajima, A. et al. (2003). Telomere dynamics in myelodysplastic syndrome determined by telomere measurement of marrow metaphases. Clin. Cancer Res., 9, 1489–96.
143. Ohshima, K., Karube, K., Shimazaki, K. et al. (2003). Imbalance between apoptosis and telomerase activity in myelodysplastic syndromes: possible role in ineffective hemopoiesis. Leuk. Lymphoma, 44, 1339–46.
144. Beausejour, C. M., Krtolica, A., Galimi, F. et al. (2003). Reversal of human cellular senescence: roles of the p53 and p16 pathways. Embo. J., 22, 4212–22.
145. Esteller, M. (2003). Profiling aberrantDNAmethylation in hematologic neoplasms: a view from the tip of the iceberg. Clin. Immunol., 109, 80–8.
146. Quesnel, B., Guillerm, G., Vereecque, R. et al. (1998).Methylationof the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood, 91, 2985–90.
147. Lubbert, M. (2003). Gene silencing of the p15/INK4B cell-cycle inhibitor by hypermethylation: an early or later epigenetic alteration in myelodysplastic syndromes? Leukemia, 17, 1762–4.
148. Christiansen, D. H., Andersen, M., and Pedersen-Bjergaard, J. (2003).Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia, 17, 1813–19.
149. Claus, R. and Lubbert, M. (2003). Epigenetic targets in hematopoietic malignancies. Oncogene, 22, 6489–96.
150. Daskalakis, M., Nguyen, T., Nguyen, C. et al. (2002). Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2’- deoxycytidine (decitabine) treatment. Blood, 100, 2957–64.
151. Lichtman, M. A. and Rowe, J. (2004). The relationship of patient age to the pathobiology of the clonal myeloid diseases. Semin. Oncol., 31, 185–97.
152. Krtolica, A. and Campisi, J. (2003). Integrating epithelial cancer, aging stroma and cellular senescence. Adv. Gerontol., 11, 109–16.
153. Busuttil, R. A., Rubio, M., Campisi, J., and Vijga, J. (2004). Genomic instability, aging, and cellular senescence. Ann. N. Y. Acad. Sci., 1019, 245–55.
154. Campisi, J. (2003). Cellular senescence and apoptosis: how cellular responses might influence aging phenotypes. l. Exp. Gerontol., 38, 5–11.
155. Krtolica, A. and Campisi, J. (2002). Cancer and aging: a model for the cancer promoting effects of the aging stroma. Int. J. Biochem. Cell Biol., 34, 1401–14.
156. Busuttil, R. A., Rubio, M., Dolle, M.E., Campisi, J., andVijg, J. (2003). Oxygen accelerates the accumulation of mutations during the senescence and immortalization of murine cells in culture. Aging Cell, 2, 287–94.
157. Sutton, J. F., Stacey, M., Kearns, W. G. et al. (2004). Increased risk for aplastic anemia andmyelodysplastic syndrome in individuals lacking glutathione S-transferase genes. Pediatr. Blood Cancer, 42, 122–6.
158. Allan, J. M., Wild, C., Rollinson, S. et al. (2001). Polymorphism in glutathione Stransferase P1 is associated with susceptibility to chemotherapy-induced leukemia. Proc. Natl Acad. Sci. U.S.A., 98, 11592–7.
159. Morgan, G. J. and Smith, M. (2002). Metabolic enzyme polymorphisms and susceptibility to acute leukemia in adults. Am. J. Pharmacogenomics, 2, 79–92.